Loading resource…
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Acute myeloid leukemia (AML) is a severe bone marrow stem cell cancer that remains challenging to treat despite advancements. The document discusses the evolution of diagnostic criteria, risk assessment methodologies, and therapeutic strategies over the past decade. It emphasizes the integration of new biological insights into classification systems and the impact of measurable residual disease (MRD) monitoring on treatment outcomes. The authors also review recent FDA-approved therapies and their implications for patient management.
No account needed